Genmab's Epcoritamab-Lenalidomide Combo Shows Strong PFS Gain in Relapsed DLBCL
Event summary
- Phase 3 EPCORE DLBCL-4 trial met primary endpoint, showing statistically significant PFS improvement in relapsed/refractory DLBCL patients.
- Epcoritamab plus lenalidomide reduced disease progression/death risk by 60% (HR 0.40) vs. standard chemoimmunotherapy.
- Trial enrolled patients who failed prior treatments, including anti-CD20 mAb-containing chemotherapy and were ineligible for CAR-T.
- Genmab plans regulatory submissions with AbbVie; data to be presented at future medical meetings.
The big picture
This positive readout strengthens Genmab's position in the bispecific antibody space, particularly for difficult-to-treat lymphomas. The chemotherapy-free regimen could reshape treatment paradigms if approved, competing directly with established CAR-T therapies and chemoimmunotherapy standards.
What we're watching
- Regulatory Strategy
- The pace at which Genmab and AbbVie secure approvals for this combination therapy will determine its commercial potential.
- Competitive Positioning
- Whether these results can position epcoritamab as a preferred option over existing CAR-T therapies in relapsed DLBCL.
- Pipeline Expansion
- How Genmab leverages this success to advance other epcoritamab combinations across hematologic malignancies.
Related topics